MacroChem to Present at the Equities Magazine Transatlantic Corporate Conference 2006

Wellesley Hills, Massachusetts (ots/PRNewswire) -

MacroChem's (OTC Bulletin Board: MACM) president and CEO, Robert
DeLuccia, will present at the upcoming Equities Magazine
Transatlantic Corporate Conference, on September 15-20, 2006. He will
appear at the American Stock Exchange on Friday, September 15, 2006
at 10:30 AM EDT, the London Stock Exchange on Monday, September 18,
2006 at 11:00 AM EDT and Borsa Italiana, in Milan on Wednesday,
September 20, 2006 at 4:00 AM EDT.

The Equities Corporate Conference is focused on bringing promising
emerging growth companies to the global investment community. The
conference includes fund managers and discretionary portfolio
managers from the United States & Europe, retail and boutique
brokerage firms, as well as sophisticated long-term retail investors.

Interested parties can access a live audio webcast of the
Company's presentation, at the date and time for both the American
Stock Exchange and the London Stock Exchange, through a link at
http://www.equitiesmagazine.com.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company with
two clinical development stage products containing our patented
enhancer, SEPA(R): EcoNail, to treat fungal infection of the nail and
Opterone(R), to treat male hypogonadism. In addition to our SEPA
technology, we are also evaluating applications for MacroDerm(TM),
our patented series of polymers that impede penetration of active
ingredients through the skin. For more information visit our website,
http://www.macrochem.com.

About Equities Magazine

EQUITIES magazine is focused on bringing together corporate
executives and corporate and institutional investment professionals
who closely follow and invest in mid cap and small cap growth
companies. Their corporate conferences now celebrate 25 years of
bridging the gap between emerging public companies and the investment
community.

Forward-Looking Statements

With the exception of historical information contained in this
press release, the matters described herein are forward-looking
statements that involve risks and uncertainties. MacroChem's actual
results may differ significantly from the results discussed in the
forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those discussed or
referred to in the section entitled "Risk Factors" in MacroChem's
Annual Report on Form 10-K, as well as those discussed elsewhere
therein, and include, without limitation, risks regarding product
development, the timing and results of clinical trials, the
regulatory approval process, capital requirements, financial
condition, patent protection and dependence on third parties for
development and licensing arrangements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. MacroChem undertakes no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise. For more information
visit our website, http://www.macrochem.com.

Contact:
MacroChem Corp.:
Bernard Patriacca - VP/CFO
+1-781-489-7310
Investor Relations:
The Investor Relations Group, Inc.
Jordan Silverstein/Christine Berni
+1-212-825-3210
Web site: http://www.macrochem.com
http://www.equitiesmagazine.com

ots Originaltext: MacroChem Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Bernard Patriacca, VP/CFO of MacroChem Corp., +1-781-489-7310; or
Jordan Silverstein or Christine Berni of The Investor Relations
Group, Inc., +1-212-825-3210